Related references
Note: Only part of the references are listed.Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives
Diego Garcia-Compean et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India
Awadhesh Kumar Singh et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2022)
Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists
Aki Okamoto et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2021)
Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis
Deep Dutta et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us?
Ahmad Al-Mrabeh
CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM (2020)
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Philip Newsome et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Sven Francque et al.
ADVANCES IN THERAPY (2019)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis
Xuejing Li et al.
ENDOCRINE (2018)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Banting Memorial Lecture 2012 Reversing the twin cycles of Type2 diabetes
R. Taylor
DIABETIC MEDICINE (2013)
Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol
E. L. Lim et al.
DIABETOLOGIA (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
